- Home
- WHD vs DNLI Comparison
WHD vs DNLI Comparison
Compare WHD & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHD | DNLI |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.2B |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WHD | DNLI |
|---|---|---|
| Price | $44.77 | $19.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $56.33 | $29.38 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | ★ 18.99 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $1,079,051,000.00 | N/A |
| Revenue This Year | $42.81 | N/A |
| Revenue Next Year | $4.93 | $291.12 |
| P/E Ratio | $243.16 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.30 | $10.57 |
| 52 Week High | $59.25 | $23.77 |
Technical Indicators
Market Signals| Indicator | WHD | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 31.83 | 45.39 |
| Support Level | $42.99 | $18.83 |
| Resistance Level | $47.39 | $20.12 |
| Average True Range (ATR) | 1.99 | 0.94 |
| MACD | -0.64 | -0.15 |
| Stochastic Oscillator | 1.75 | 30.69 |
Price Performance
Historical ComparisonAbout WHD Cactus Inc.
Cactus Inc is engaged in the designing, manufacturing, and sale of wellheads and pressure control equipment. Its principal products include Cactus SafeDrill wellhead systems, conventional wellheads, and production valves among others. The company also provides mission-critical field services, including service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents. It sells or rents its products principally for onshore unconventional oil and gas wells that are utilized during the drilling, completion (including fracturing), and production. It has two operating segments; Pressure Control, which generates key revenue and Spoolable Technologies.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.